Alex­ion co-founder Stephen Squin­to is back in the game as CEO, this time for a small gene ther­a­py play­er

With his name al­ready be­hind a rare dis­ease suc­cess sto­ry in Alex­ion, Stephen Squin­to was look­ing for a great sto­ry to dri­ve him to jump back in­to the biotech game. He found that in a fledg­ing non-vi­ral gene ther­a­py com­pa­ny, and now he’s got a few back­ers on board as well.

On Tues­day, Gen­nao Bio launched with a $40 mil­lion Se­ries A co-led by Or­biMed and Lo­gos Cap­i­tal with par­tic­i­pa­tion by Sur­vey­or Cap­i­tal. The biotech, which is look­ing to use its cell-pen­e­trat­ing an­ti­body plat­form to de­liv­er nu­cle­ic acid “pay­loads” dur­ing in­to the nu­cle­us, had to rush for its ini­tial se­ries — and had a name change along the way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER